ХОЛЕСТЕРИНОВАЯ АТЕРОЭМБОЛИЯ КАК ПРИЧИНА НАРУШЕНИЯ РЕПЕРФУЗИИ МИОКАРДА ПРИ ЭНДОВАСКУЛЯРНОМ ВОССТАНОВЛЕНИИ КОРОНАРНОГО КРОВОТОКА (ОБЗОР ЛИТЕРАТУРЫ)
Борис Суковатых,
Николай Боломатов,
Дмитрий Сидоров,
Михаил Суковатых,
Арсен Григорьян,
Александр Груздов Abstract
В статье проанализированы данные отечественной и зарубежной литературы, раскрывающие проблему нарушений коронарного кровотока при эндоваскулярных вмешательствах. С современных позиций представлена роль различных факторов риска развития нарушения реперфузии миокарда. Описаны способы клинической и инструментальной диагностики феноменов замедленного и невосстановленного коронарного кровотока. Подчеркнута необходимость индивидуального подхода к применению лекарственных препаратов для купирования коронарных нарушений. Акцентировано внимание на современных способах инструментальной профилактики холестериновой атероэмболии. Указано на необходимость исключения рутинной тромбэктомии при чрескожных коронарных вмешательствах.
About the Authors
Борис СуковатыхRussian Federation
Николай Боломатов
Russian Federation
Дмитрий Сидоров
Russian Federation
Михаил Суковатых
Russian Federation
Арсен Григорьян
Курский государственный медицинский университет
Russian Federation
Russian Federation
Александр Груздов
Russian Federation
References
1. Ozkok A. Cholesterol-embolization syndrome: current perspectives. Vasc Health Risk Manag. 2019; 15: 209-220. doi: 10.2147/VHRM.S175150
2. Pantea-Roșan LR, Bungau SG, Radu AF, Pantea VA, Moisi MI, Vesa CM, Behl T, Nechifor AC, Babes EE, Stoicescu M, Gitea D, Iovanovici DC, Bustea C. A Narrative Review of the Classical and Modern Diagnostic Methods of the No-Reflow Phenomenon. Diagnostics (Basel). 2022; 12(4): 932. doi: 10.3390/diagnostics12040932
3. Shahri B, Vojdanparast M. Coronary No-reflow Phenomenon: A Review of Therapeutic Pharmacological Agents. Razavi International Journal of Medicine. 2020; 8(1-4): e1002. doi: 10.30483/rijm.2020.254145.1002
4. Gerasimov AM, Tereshchenko AS, Merkulov EV, Samko AN. No-reflow phenomenon in the practice of an endovascular surgeon. Journal of radiology and nuclear medicine. 2014;(1):51-55. (In Russ.) doi: 10.20862/0042-4676-2014-0-1-51-55
5. Majno G, Ames A, Chaing J, Wright RL. No reflow after cerebral ischemia. Lancet. 1967; 290(7515): 569-570. doi: 10.1016/S0140-6736(67)90552-1
6. Khalirakhmanov AF, Gaziev EA, Sharafeev AZ, Sharafutdinov BM. Development of "no-reflow" phenomenon after percutaneous coronary interventions: current aspects. Diagnostic and Interventional Radiology. 2019; 13(4): 57-66. (In Russ) doi: 10.25512/DIR.2019.13.4.06
7. Shah M, Mohsin M, Satti KN. Predictors and in-hospital mortality of slow flow/no-reflow after percutaneous coronary intervention in patients with ST-elevation myocardial infarction. Journal of Akhtar Saeed Medical & Dental College. 2023; 5(03): 144-151. doi: 10.51127/JAMDCV5I3OA05
8. Avci E, Yildirim T, Aydin G, Kiris T, Dolapoglu A, Kadi H, Safak O, Bayata S. Combining clinical predictors to better predict for the no-reflow phenomenon. Eur Rev Med Pharmacol Sci. 2018; 22(15): 4987-4994. doi: 10.26355/eurrev_201808_15639
9. Savic L, Mrdovic I, Asanin M, Stankovic S, Lasica R, Krljanac G, Rajic D, Simic D. The Impact of Kidney Function on the Slow-Flow/No-Reflow Phenomenon in Patients Treated with Primary Percutaneous Coronary Intervention: Registry Analysis. J Interv Cardiol. 2022; 2022: 5815274. doi: 10.1155/2022/5815274
10. Kai T, Oka S, Hoshino K, Watanabe K, Nakamura J, Abe M, Watanabe A. Renal Dysfunction as a Predictor of Slow-Flow/No-Reflow Phenomenon and Impaired ST Segment Resolution After Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction With Initial Thrombolysis in Myocardial Infarction Grade 0. Circ J. 2021; 85(10): 1770-1778. doi: 10.1253/circj.CJ-21-0221
11. Hu X, Yang X, Li X, Li G, Zhou Y, Dong H. Elevated uric acid is related to the no-/slow-reflow phenomenon in STEMI undergoing primary PCI. Eur J Clin Invest. 2022; 52(4): e13719. doi: 10.1111/eci.13719
12. Somuncu MU, Akgun T, Cakır MO, Akgul F, Serbest NG, Karakurt H, Can M, Demir AR. The Elevated Soluble ST2 Predicts No-Reflow Phenomenon in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. J Atheroscler Thromb. 2019; 26(11): 970-978. doi: 10.5551/jat.48413
13. Zhang Q, Hu M, Ma S. Association of Soluble Suppression of Tumorigenicity with No-Reflow Phenomenon and Long-Term Prognosis in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome after Percutaneous Coronary Intervention. J Atheroscler Thromb. 2021; 28(12): 1289-1297. doi: 10.5551/jat.59832
14. Sondergaard FT, Beske RP, Frydland M, Moller JE, Helgestad OKL, Jensen LO, Holmvang L, Goetze JP, Engstrom T, Hassager C. Soluble ST2 in plasma is associated with post-procedural no-or-slow reflow after primary percutaneous coronary intervention in ST-elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2023; 12(1): 48-52. doi: 10.1093/ehjacc/zuac146
15. Li Y, Liang X, Zhang W, Qiao X, Wang Z. The Clinical and Angiographic Outcomes of Postdilation after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis. J Interv Cardiol. 2021; 2021: 6699812. doi: 10.1155/2021/6699812
16. Fajar JK, Heriansyah T, Rohman MS. The predictors of no reflow phenomenon after percutaneous coronary intervention in patients with ST elevation myocardial infarction: A meta-analysis. Indian Heart J. 2018; 70(3): S406-S418. doi: 10.1016/j.ihj.2018.01.032
17. Gupta S, Gupta MM. No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction. Indian Heart J. 2016; 68(4): 539-51. doi: 10.1016/j.ihj.2016.04.006
18. Abtan J, Wiviott SD, Sorbets E, Popovic B, Elbez Y, Mehta SR, Sabatine MS, Bode C, Pollack CV, Cohen M, Moccetti T, Laanmets P, Faxon D, Okreglicki A, Ducrocq G, Steg PG; TAO investigators. Prevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial. Arch Cardiovasc Dis. 2021; 114(3): 187-196. doi: 10.1016/j.acvd.2020.09.005
19. Agrawal A, Ziccardi MR, Witzke C, Palacios I, Rangaswami J. Cholesterol embolization syndrome: An under-recognized entity in cardiovascular interventions. J Interv Cardiol. 2018; 31(3): 407-415. doi: 10.1111/joic.12483
20. Alief W, Mukti CN, Henry S. Cholesterol crystal embolism: Unraveling its impact on atherosclerotic cardiovascular diseases. Journal of Medicine, Surgery, and Public Health. 2024; 3: 100102. DOI: 10.1016/j.glmedi.2024.100102
21. Sinha SK, Kumar P, Sharma AK, Razi M, Pandey U, Sachan M, Shukla P, Aggarwal P, Jha MJ, Thakur R, Krishna V. Perforated balloon technique mediated intracoronary delivery of nicorandil to treat coronary no-reflow phenomenon: a novel pharmacological solution to precarious situation. Am J Cardiovasc Dis. 2021; 11(5): 544-554.
22. Allencherril J, Jneid H, Atar D, Alam M, Levine G, Kloner RA, Birnbaum Y. Pathophysiology, Diagnosis, and Management of the No-Reflow Phenomenon. Cardiovasc Drugs Ther. 2019; 33(5): 589-597. doi: 10.1007/s10557-019-06901-0
23. Hu X, Wang W, Ye J, Lin Y, Yu B, Zhou L, Zhou Y, Dong H. Effect of GP IIb/IIIa inhibitor duration on the clinical prognosis of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction with no-/slow-reflow phenomenon. Biomed Pharmacother. 2021; 143: 112196. doi: 10.1016/j.biopha.2021.112196
24. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann FJ, Van de Werf F, Antman EM, Topol EJ. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA. 2005; 293(14): 1759-1765. doi: 10.1001/jama.293.14.1759
25. Petronio AS, Rovai D, Musumeci G, Baglini R, Nardi C, Limbruno U, Palagi C, Volterrani D, Mariani M. Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty. Eur Heart J. 2003; 24(1): 67-76. doi: 10.1016/s0195-668x(02)00324-1
26. Simoons ML; GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. The Lancet. 2001; 357(9272): 1915-24. doi: 10.1016/S0140-6736(00)05060-1
27. Sukhinina TS, Pevzner DV, Mazurov AV, Vlasik TN, Solovieva NG, Kostritca NS, Shakhnovich RM, Yavelov IS. The role of platelet glycoprotein IIb / IIIa inhibitors in current treatment of acute coronary syndrome. Kardiologiia. 2022; 62(4): 64-72. (In Russ) doi: 10.18087/cardio.2022.4.n2020
28. Callichurn K, Simard P, De Marco C, Jamali P, Saada Y, Matteau A, Schampaert E, Mansour S, Hatem R, Potter BJ. A dual-center analysis of conservative versus liberal glycoprotein IIb-IIIa antagonist strategies in the treatment of ST-elevation myocardial infarction. Sci Rep. 2024; 14(1): 15003. doi: 10.1038/s41598-024-64652-x
29. Bocchino PP, Angelini F, Gallone G, Frea S, De Ferrari GM. The cardiovascular safety of sodium nitroprusside in acute heart failure. Expert Opin Drug Saf. 2024; 23(6): 663-666. doi: 10.1080/14740338.2024.2348570
30. Berg R, Buhari C. Treating and preventing no reflow in the cardiac catheterization laboratory. Current cardiology reviews. 2012; 8(3): 209-214.
31. Procopio MC, Lauro R, Nasso C, Carerj S, Squadrito F, Bitto A, Di Bella G, Micari A, Irrera N, Costa F. Role of Adenosine and Purinergic Receptors in Myocardial Infarction: Focus on Different Signal Transduction Pathways. Biomedicines. 2021; 9(2): 204. doi: 10.3390/biomedicines9020204
32. Laborante R, Bianchini E, Restivo A, Ciliberti G, Galli M, Vergallo R, Rodolico D, Zito A, Princi G, Leone AM, Aurigemma C, Romagnoli E, Montone RA, Burzotta F, Trani C, Crea F, D'Amario D. Adenosine as adjunctive therapy in acute coronary syndrome: a meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother. 2023; 9(2): 173-182. doi: 10.1093/ehjcvp/pvac069
33. Grancini L, Diana D, Centola A, Monizzi G, Mastrangelo A, Olivares P, Montorsi P, Alushi B, Bartorelli AL, Galassi AR. The SALINE Technique for the Treatment of the No-Reflow Phenomenon during Percutaneous Coronary Intervention in STEMI. J Clin Med. 2023; 12(6): 2405. doi: 10.3390/jcm12062405
34. Egred M, Bagnall A, Spyridopoulos I, Purcell IF, Das R, Palmer N, Grech ED, Jain A, Stone GW, Nijveldt R, McAndrew T, Zaman A. Effect of Pressure-controlled intermittent Coronary Sinus Occlusion (PiCSO) on infarct size in anterior STEMI: PiCSO in ACS study. Int J Cardiol Heart Vasc. 2020; 28: 100526. doi: 10.1016/j.ijcha.2020.100526
35. Gibson CM, Ajmi I, von Koenig CL, Turco MA, Stone GW. Pressure-Controlled Intermittent Coronary Sinus Occlusion: A Novel Approach to Improve Microvascular Flow and Reduce Infarct Size in STEMI. Cardiovasc Revasc Med. 2022; 45: 9-14. doi: 10.1016/j.carrev.2022.07.007
36. Texakalidis P, Letsos A, Kokkinidis DG, Schizas D, Karaolanis G, Giannopoulos S, Giannopoulos S, Economopoulos KP, Bakoyannis C. Proximal embolic protection versus distal filter protection versus combined protection in carotid artery stenting: A systematic review and meta-analysis. Cardiovasc Revasc Med. 2018; 19(5 Pt A): 545-552. doi: 10.1016/j.carrev.2017.12.010
37. Giannopoulos S, Sagris M, Giannopoulos S, Tzoumas A, Kokkinidis DG, Texakalidis P, Koutsias G, Volteas P, Jing L, Malgor RD. Embolic protection devices for carotid artery stenting: A network meta-analysis. Vascular. 2024; 32(2): 447-457. doi: 10.1177/17085381221140616
38. Celik M, Yuksel UC, Yalcinkaya E, Gokoglan Y, Iyisoy A. Conservative treatment of iatrogenic left main coronary artery dissection: report of two cases. Cardiovasc Diagn Ther. 2013; 3(4): 244-246. doi: 10.3978/j.issn.2223-3652.2013.10.04
39. De Luca L, Sardella G, Davidson CJ, De Persio G, Beraldi M, Tommasone T, Mancone M, Nguyen BL, Agati L, Gheorghiade M, Fedele F. Impact of intracoronary aspiration thrombectomy during primary angioplasty on left ventricular remodelling in patients with anterior ST elevation myocardial infarction. Heart. 2006; 92(7): 951-957. doi: 10.1136/hrt.2005.074716
40. Satti Z, Omari M, Bawamia B, Cartlidge T, Egred M, Farag M, Alkhalil M. The Use of Thrombectomy during Primary Percutaneous Coronary Intervention: Resurrecting an Old Concept in Contemporary Practice. J Clin Med. 2024; 13(8): 2291. doi: 10.3390/jcm13082291
41. Zhou L, Hu X, Zhang H, Lu H, Lin Y, Wang W, Yu B, Liang W, Zhou Y, Li G, Dong H. Effects of atorvastatin and rosuvastatin on dysfunctional coronary circulation in patients with ST-segment elevation myocardial infarction. J Int Med Res. 2023; 51(6): 3000605231182547. doi: 10.1177/03000605231182547
42. Mikhailova ZD, Klimkin PF. Cholesterol Atheroembolism Syndrome: Current State of the Problem. The Russian Archives of Internal Medicine. 2020; 10(4): 272-280. (In Russ) doi: 10.20514/2226-6704-2020-10-4-272-280
Supplementary files
|
1. Неозаглавлен | |
| Subject | ||
| Type | Other | |
Download
(22KB)
|
Indexing metadata ▾ | |
|
2. Неозаглавлен | |
| Subject | ||
| Type | Other | |
Download
(677KB)
|
Indexing metadata ▾ | |
Review
For citations:
, , , , , . Complex Issues of Cardiovascular Diseases. 2026;15(1):72-83. (In Russ.)
Views:
94
JATS XML
